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ONLINE MUTATION REPORT
Novel mutations in the KCNQ2 gene link epilepsy to a
dysfunction of the KCNQ2-calmodulin interaction
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utations in the voltage gated potassium channels
KCNQ2 (OMIM 602235) and KCNQ3 (OMIM
602232) are associated with an autosomal dominant
idiopathic epilepsy syndrome of newborns, benign familial
neonatal seizures (BFNS) (OMIM 121200). BFNS is char-
acterised by unprovoked partial seizures typically beginning
when the infant is around three days old. BFNS associated
genes were mapped to human chromosomes 20q13.31 and
8q24,2 which led to the identification by positional cloning of
KCNQ2 as the chromosome 20 gene.3 4 KCNQ3 was subse-
quently identified as the 8q24 BFNS gene, based on genomic
location and homology with KCNQ2.5
The potassium channels of the KCNQ gene family consist
of four subunits, each with a 6 transmembrane topological
organisation. KCNQ subunits, comprising KCNQ1–5, have an
intracellular amino terminus, a single pore loop (P-loop) that
forms the selectivity filter of the channel,6 a positively
charged, voltage sensing fourth transmembrane domain
(S4), and a large intracellular carboxy terminus (C-termi-
nus). All five known KCNQ proteins can form homomeric
channels, but the association of specific subunits to form
heteromeric channels is restricted to certain combinations.6–10
KCNQ2 and KCNQ3 are mostly expressed in the central
nervous system,3–5 where they form a heteromultimeric
channel that mediates the neuronal muscarinic regulated
current (M-current), also known as an M-channel (or M-type
K+ channel). The M-current is a slowly activating, non-
inactivating potassium conductance known to regulate
neuronal excitability by determining the firing properties of
neurones and their responsiveness to synaptic input.11
Because it is active at voltages near the threshold for action
potential initiation, the M-current has a major impact on
neuronal excitability.
Since the KCNQ2/KCNQ3 ion channel plays a pivotal role
in the regulation of neuronal excitability, it is not surprising
that several mutations in the gene have been associated with
epilepsy. The first K+ channel mutations associated with
epilepsy were reported in 19983 4 and more have subsequently
been reported in both KCNQ2 and KCNQ3.
Whilst it is generally hypothesised that mutations in either
KCNQ2 or KCNQ3 may result in a mild reduction of the M-
current and subsequent dysfunction of the neuronal response
to synaptic input, for the most part no significant dominant
negative effects or alterations in channel gating or ion
selectivity have been observed.3 7 12 13 In one BFNS family, a
mutation in the voltage-sensing S4 domain of KCNQ2 was
shown to have a dominant negative effect on channel
activation; however this was associated with the occurrence
of myokymia in patients.14
KCNQ2 C-terminal mutations account for over half of all
known mutations associated with BFNS and to date there
have been no functional studies elucidating the pathogenic
effects of such mutations. Recently, the interaction between
the C-terminal region of KCNQ2 and the ubiquitous calcium
binding protein calmodulin (CaM) has been reported,15–17
suggesting a possible pathogenic mechanism of action for C-
terminal KCNQ2 mutations.
Here, we report the association of eight novel KCNQ2
mutations in families with benign familial neonatal seizures.
Specifically, we show that two missense mutations affect the
binding affinity of CaM and we discuss the involvement of an
aberrant KCNQ2-CaM interaction in epileptogenesis.
MATERIALS AND METHODS
Clinical data
Detailed clinical histories and pedigrees were obtained from
families where two or more individuals had neonatal
seizures, without a known extraneous cause. Venous blood
was sampled for DNA extraction. The study was approved by
the Austin and Repatriation Medical Centre Committee on
Human Ethics.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Abbreviations: BFNS, benign familial neonatal seizures; CaM,
calmodulin; C-terminus, carboxy terminus; KCNQ2, Homo sapiens
potassium voltage gated channel, KQT-like subfamily, member 2;
KCNQ3, Homo sapiens potassium voltage gated channel, KQT-like
subfamily, member 3; P-loop, pore loop; M-current, neuronal muscarinic
regulated current; S1–6, first to sixth transmembrane domains
Key points
N We set out to ascertain KCNQ2 mutations in 10
families with benign familial neonatal seizures (BFNS),
and to determine if any mutations from the C-terminal
region affected the interaction between KCNQ2 and
the ubiquitous calcium sensing protein, calmodulin
(CaM).
N Eight novel mutations were found: two missense start
codon mutations and a frameshift mutation in the N-
terminal region and a truncation, two putative splice
site mutations and two missense mutations in the C-
terminal region.
N Using a yeast two hybrid assay, we determined that the
KCNQ2 C-terminal missense mutations R353G and
L619R both affect normal CaM binding. The R353G
mutation lies within one of the two putative CaM
binding regions and the L619R lies within close
proximity of the other.
N On the basis of our data we postulate that dysfunction
of CaM binding may be one of the pathogenic
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Mutation screening
KCNQ2 was screened by single strand conformation poly-
morphism analysis or sequencing as described elsewhere.18
Primer sequences for these and all other primers from the
study are available from the authors upon request.
Generation of yeast two-hybrid screen constructs
A yeast two hybrid screen was carried out using the
ProQuestTM Two-Hybrid System with GatewayTM
Technology (InvitrogenTM, Australia) according to the manu-
facturer’s directions. A KCNQ2 C-terminal entry clone was
generated using the pENTR Directional TOPOH Cloning Kit
(InvitrogenTM, Australia). Primers were designed to amplify
the intracellular C-terminal region of KCNQ2 based on the
sequence of human KCNQ2 (Genbank accession number
NM_172107). The 1611 bp cloned fragment included exon
10a (found in all our amplified clones), corresponding to aa
373–382.3 19 The extra 30 bp (10 aa) were included in our
numbering. Following sequence verification, the KCNQ2
cDNA fragment was then subcloned into pDESTTM32, the
DNA Binding domain (DB) GatewayTM Destination Vector
(InvitrogenTM, Australia).
KCNQ2 C-terminal bait mutagenesis
Primers were designed to incorporate the c.1057C.G
(R353G) and c. 1856T.G (L619R) changes into the
pDESTTM32- KCNQ2 C-terminal bait construct. Overlapping
PCR products were amplified, gel extracted and purified
before a second round of PCR using the initial KCNQ2 F and
R primers. These products were also gel extracted before
cloning into the pDESTTM32 bait vector using the TOPOH
system. Mutant baits were sequence verified.
Yeast two-hybrid assay
The DBLeu (empty bait vector), DB-KCNQ2 wild-type (DB-
Q2C wt) and mutant (R353G, L619R) C-term baits were
transformed into the yeast strain Mav203 and plated onto
minimal selective media lacking leucine. A duplicate was
carried out, in which the empty Activation Domain (pAD)
prey vector was cotransformed with the baits and plated onto
minimal selective media lacking leucine (2Leu) and trypto-
phan (2Trp). Yeast control strains (InvitrogenTM) were
included on all plates. Control 1, used as a negative control,
contains empty plasmids pPC97 and pPC86. Control 2 has
pPC97-RB and pPC86-E2F1, which express a relatively weak
interaction. Control 3 contains plasmids encoding the
Drosophila DP (pPC97) and E2F (pPC86) domains that have
a moderately strong interaction, and provide a control for
plasmid shuffling. Control 4 contains pPC97-Fos and pPC86-
Jun which express a relatively strong interaction, and control
5 has a pCL1 plasmid encoding full-length GAL4p and empty
pPC86 and is used as a positive control. The constructs were
tested for self-activation of the HIS3 and b-galactosidase
reporter genes according to InvitrogenTM instructions. The
interaction between each DB-Q2C mutant and CaM was then
tested by yeast two-hybrid assay and compared to the
interaction with DB-Q2 wt. Three different PCR amplified
CaM clones were introduced by gap repair20 into the prey
vector (pPC86) in the yeast strain expressing either DB-Q2C
wt, DB-Q2C mutants, or the empty DBLeu vector, which was
used as a negative control. CaM interaction with the DB-Q2C
wt and mutants was then assessed by expression of the HIS3
and LacZ reporter genes.
Yeast protein extraction
Yeast cultures were prepared for protein extraction according
to the Clontech protocol. Protein extracts were prepared by
the Urea and sodium dodecyl sulphate method described
elsewhere.21
Western blotting
The NuPageH Novex 4–12% Bis-Tris Pre-cast gel system
(InvitrogenTM, Australia) was used to analyse the yeast
protein extracts. Gels were run according to the manufac-
turer’s instructions. A 42 kDa Gal4 (DBD-1–147) positive
control (Santa Cruz Biotechnology, Inc., Santa Cruz,
California) and MagicMarkTM Western Protein Standard
(InvitrogenTM, Australia) were run on the gel for comparison.
A 1:1000 dilution of the mouse monoclonal Gal4 (DBD)
antibody (RK5C1, Santa Cruz Biotechnology, Inc., Santa
Cruz, CA) was used as the primary antibody, followed by a
1:5000 dilution of the horseradish peroxidase conjugated
sheep antimouse immunoglobulin secondary antibody
(Silenus Labs, Pty. Ltd., Australia). The membrane was
visualised with SuperSignalH West Dura Extended Duration
Substrate (Pierce Biotechnology, Inc., Rockford, IL).
Assay for b-galactosidase activity in liquid culture
using chlorophenol red-b-D-galactopyranoside
The chlorophenol red-b-D-galactopyranoside assay was car-
ried out according to the ProQuestTM Two-Hybrid System
with GatewayTM Technology (InvitrogenTM, Australia)
instructions. The units of b-galactosidase in each sample
were calculated, where 1 unit of b-galactosidase is defined as
the amount that hydrolyses 1 mmol of chlorophenol red-b-D-
galactopyranoside to chloramphenicol red and D-galactose in
one minute:
where V = volume of culture used in the assay (ml);
OD574 = optical density at 574 nm, which is equal to the
absorbance by chloramphenicol red (and light scattering by
cell debris); OD600 = optical density at 600 nm, which is equal
to the cell density at the start of the assay. Data were
analysed with MicrosoftH Excel 2000 and for statistical
evaluation, a two-tailed, unpaired Student’s t test was
applied.
RESULTS AND DISCUSSION
Novel KCNQ2 mutations were found in eight out of ten BFNS
families in our study. All of the mutations were found on one
allele only (—that is, patients were heterozygous) and were
shown to segregate within the families. None of the
mutations were detected in at least 50 unaffected control
samples. The novel mutations that we found comprised two
mutations of the start codon (M1V, M1T), one frameshift
(K69fsX119), one truncation (R430X), two putative splice
site mutations (E491 and R570) and two missense mutations
(R353G and L619R) (table 1 and fig 1). The one base
insertion at aa 69 creates a premature termination of the
protein within the N-terminal domain of KCNQ2 and, along
with the two mutations of the start codon, would act as an
allelic knockout, likely to result in decreased KCNQ2 subunit
expression and a concomitant reduction in neuronal M-
channels. The subsequent reduction in M-current in the brain
is predicted to result in reduced inhibition of neuronal
excitability, resulting in hyperexcitability as observed in
benign familial neonatal seizures. The other five mutations
are all located within the KCNQ2 C-terminal domain. All
known mutations are shown in table 1 and fig 1.
To date, most functional studies have been on mutations
located within transmembrane domains. In particular muta-
tions associated with BFNS and found in the voltage sensing
S4 domain of KCNQ2 were shown to alter the gating
properties of the M-channels, displaying slower opening
and faster closing kinetics and a decreased voltage sensitivity
2 of 6 Online mutation report
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with no concomitant changes in maximal current or
membrane expression.14 28 29
Effects of mutations in the KCNQ2 C-terminal domain are
less well understood, although the cytoplasmic C-terminal
domain of KCNQ2 has been shown to be crucial for normal
activity of the channel.12 13 19 30 31 The C-terminus accounts for
63% of the KCNQ2 protein and, in common with other KCNQ
subunits, contains a conserved ‘‘A domain’’6 13 32 thought to
be involved in subunit interactions and another distal short
conserved region that has been associated with subunit
assembly, at least in KCNQ1.6 32 The subunit interaction
domain, encompassing the A domain and the putative
assembly domain, was recently found to determine the
subunit specificity of KCNQ channel assembly,31 and conse-
quently is essential for expression of functional homomeric or
heteromeric channels. Heteromeric KCNQ2/KCNQ3 channels
are expressed pre and postsynaptically, where they are likely
to be associated with the cytoskeleton by means of scaffold-
ing proteins. KCNQ2, because it is more resistant to detergent
than KCNQ3, is hypothesised to contain a region, such as the
subunit interaction domain, that is essential for such
cytoskeletal interactions.33 Mutations within the KCNQ2 C-
terminus clearly have the potential to disrupt subunit
assembly and may explain why no dominant negative effects
were observed in functional studies of a C-terminal truncat-
ing mutation.3 6
Two C-terminal missense mutations (R353G and L619R)
were found in families A and B respectively (fig 2) and were
subject to detailed study, to assess their effect on CaM
binding. The corresponding nucleotide changes (R353G:
c.1057CRG, L619R: c.1856TRG) were introduced into a
DB-Q2C construct by mutagenesis. The empty bait plasmid
(DBLeu), DB-Q2C wt, DB-Q2C R353G mutant or DB-Q2C
L619R mutant plasmids were transformed into Mav203 yeast
strain as indicated in fig 3A and protein expression was
confirmed by Western blotting (data not shown). The
interaction between each DB-Q2C mutant bait and CaM
was then tested by yeast two hybrid assay and compared with
the interaction with DB-Q2 wt and the control interactions.
Fig 3B shows the growth of transformed yeast and controls
on –Leu –Trp selection after 24 h. Yeast can grow on –Leu if
they contain the DB plasmid, and –Trp if they have the AD
plasmid. Fig 3C shows growth of transformed yeast and
controls on –Leu –Trp –His +40 mM 3AT selective plate after
48 h. Only yeast cells where the expression of the His3
reporter gene is activated by interaction between the bait and
prey plasmids can grow on this selective plate. Figs 3D–F
show a LacZ Filter assay for interaction between bait and prey
plasmids after 2, 7, and 24 h, respectively. A change in colour
from cream to blue indicates activation of the b-galactosidase
reporter gene by interaction of the bait and prey plasmids.
The Q2C R353G mutant did not interact with CaM, as seen by
no growth on HIS3 selective plate (fig 3C) and no blue
readout in the LacZ filter assay (figs 3D–F). On the other
hand, the DB-Q2C L619R mutant was shown still to interact
with CaM, as seen by growth on an HIS3 selective plate
(fig 3C) and the blue readout in the LacZ filter assay (figs 3D–
F). Interestingly, the DB-Q2C L619R mutant showed an even
greater growth level on HIS3 selective plate than the DB-Q2C
wt and also appeared to stain faster and more intensely blue
in the LacZ filter assay, suggesting a stronger interaction
between CaM and this mutant.
To quantify b-galactosidase activity more accurately, a
second assay was carried out using the high sensitivity
substrate chlorophenol red-b-D-galactopyranoside in liquid
culture. The affinity of the DB-Q2C/AD-CaM interaction
was measured in terms of units of b-galactosidase activity,
with a zero value indicating no expression of the LacZ
reporter gene, and hence no interaction. In the chlorophenol
red-b-D-galactopyranoside assay, a value of 0.05 units b-
galactosidase activity (fig 4) was significantly different from
the empty bait vector replicate (p,0.01, Student’s t test),
confirming the interaction of the DB-Q2C wt with CaM. As
observed in the LacZ filter assay, the chlorophenol red-b-D-
galactopyranoside assay showed a significant difference in
the interaction between the Q2C R353G mutant and CaM as
compared to the wild-type replicate (p,0.01, Student’s t
test, fig 4).
These results suggest that the R353G mutation alters the
structural conformation of the KCNQ2 C-terminal domain
such that it is no longer able to bind to CaM. Indeed, the
R353G missense mutation is within one of the CaM binding
domains previously identified in KCNQ215 16 (fig 1). By
abolishing CaM binding, the R353G mutation could lead to
an impairment of M-current in vivo, through decreased
opening of the channel. This might be predicted to have a
similar effect on neuronal excitability to truncation and
frameshift BFNS mutations that disrupt the structure of the
KCNQ2 protein.
This is supported by experiments where KCNQ2 mutants
deficient in CaM binding co-expressed with KCNQ3 in
Chinese hamster ovary cells did not give rise to detectable
currents.15 The membrane targeting of the mutants was not
altered, neither was the ability to co-assemble with KCNQ3,
thus demonstrating that CaM binding is not necessary for
membrane biogenesis of KCNQ2 or KCNQ3 channels.
Furthermore, it has been suggested that some ion channel
proteins have a binding sites for Ca2+-calmodulin.34 When
this site is not occupied, the channel is in its inactivated
(closed) conformation, but in response to an influx or
internal release of Ca2+, calcified CaM binds to the channel,
resulting in an activated (openable) form. Indeed, CaM was
shown in two studies to be tethered constitutively to the M-
channel, suggesting that the C-terminal domain of KCNQ
channels may fold in a manner that allows CaM to induce M-
channel opening.15 16
Table 1 Summary of known BFNS mutations in the
KCNQ2 potassium channel subunit. Numbering is based
on the long form of KCNQ2 (including exon 10a)
Variant Amino Acid change Location
c.1ARG* M1V (no start) N-ter
c.2TRC* M1T (no start) N-ter
c.204insC* K69fsX119 N-ter












c.1221+2TRG25 Splice donor site (K407) C-ter
c.1288CRT* Truncation (R430X) C-ter
Unknown22 R458X C-ter
c.1471+1GRA* Splice donor site (E491) C-ter
c.1510del134 S504fsX506 C-ter
c.1575+1GRA4 Splice donor site (C526) C-ter
c.1630insGCCCT3 Y544fsX549 C-ter
c.1688GRA22 R563Q C-ter




c. 2543delG12 G848fsX911 C-ter
*Our data; Numbering according to authors; `Phenotype not compatible
with typical benign familial neonatal seizures
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In contrast, the chlorophenol red-b-D-galactopyranoside
assay for the L619R Q2C mutant showed a significantly
higher level of b-galactosidase activity (0.26 units) than the
wild-type replicate (p,0.001, Student’s t test, fig 4). This
finding indicates that the L619R mutation alters the
conformation of the protein in a manner that increases
CaM binding to the KCNQ2 C-terminal domain approxi-
mately fivefold.
More recent work by Gamper and Shapiro17 is consistent
with a role for CaM in Ca2+ sensing rather than in channel
assembly (as found by Wen and Levitan15 and Yus-Na´jera et
al16), or at least a dual role for CaM in KCNQ channel
physiology. Their work suggests that bradykinin modulation
of the M-current, at least in sympathetic neurones, uses CaM
in concert with rises in calcium concentration ([Ca2+]), over
the physiological range of ,10–400 nM.
KCNQ2 and KCNQ3 channels are strongly modulated by
several distinct signalling pathways in neurones that are
mediated by second messengers,17 and these include M1-type
muscarinic receptors and activators of G-protein coupled
receptors, such as bradykinin B2
35 and purinergic P2Y2.
36 The
signal provoked by the latter two receptors involves the
phospholipase C/inositol triphosphate (PLC/IP3) pathway and
release of Ca2+ from internal stores to produce rises in
intracellular [Ca2+].35 37–39
Gamper and Shapiro17 show that bradykinin induced rises
in intracellular [Ca2+] act on M-channels via Ca2+-CaM to
suppress the M-current. In the case of the KCNQ2 L619R
Figure 1 Model of the KCNQ2 channel protein showing the known mutations associated with BFNS, numbered according to the mutated residue.
Numbering is based on the long form of KCNQ2 including exon 10a. # nomenclature according to the authors (see table 1). Grey regions of the C-
terminal loop indicate CaM binding regions.15 16
Figure 2 Pedigrees of families with benign familial neonatal seizures.
*, members carrying a KCNQ2 mutation that have been tested; 2,
members who were tested and are negative for the mutation.
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mutation that results in increased binding of CaM to the M-
channel, it can be inferred that the effect of bradykinin
modulation of M-channels would be amplified because of a
likely increased sensitivity to [Ca2+]. Thus, in the case of the
L619R mutant channel, in response to a rise in bradykinin-
induced intracellular [Ca2+], the KCNQ2/KCNQ3 derived M-
current would be suppressed to a greater extent than for the
wild-type channel. Suppression of the M-current would lead
to decreased inhibition of neuronal excitability and could
potentially be associated with BFNS pathogenicity.
CONCLUSION
Our results implicate CaM in the pathogenesis of epilepsy
and specifically in the BFNS syndrome. Whilst further work
will be required to elucidate fully the involvement of the
KCNQ2-CaM interaction in neuronal excitability and its
correlation with idiopathic epilepsy, these data suggest that
dysfunction of this interaction leads to aberrant neuronal
excitability in some BFNS patients.
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